Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) had its price objective lowered by equities research analysts at Guggenheim from $24.00 to $23.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s price target would indicate a potential upside of 101.14% from [...]
Zevra Therapeutics (NASDAQ:ZVRA) Price Target Lowered to $23.00 at Guggenheim
